Jeff Yass’s Aspire Biopharma ASBP Stock Holding History

Jeff Yass’s Portfolio ASBP Stock Details ASBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-13	Closed	-$9.34K	–	13993
2025 Q1	$9.34K	Buy	+13	New	+$89.9K	﹤0.01%	12219

Other funds holding ASBP

Procyon Advisors Shelton, Connecticut $2.32B AUM 26.81% 1-Year Est. Return

Crewe Advisors Salt Lake City, Utah $1.38B AUM 41.76% 1-Year Est. Return

Optivise Advisory Services Franklin, Tennessee $197M AUM 26.07% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

VR Advisory Services Camana Bay, Grand Cayman, Cayman Islands $1.13B AUM 38.97% 1-Year Est. Return

Three Seasons Wealth Salt Lake City, Utah $1.1B AUM 50.99% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return

Valley Wealth Managers Paramus, New Jersey $1.73B AUM 42.12% 1-Year Est. Return

Platform Technology Partners New York $611M AUM 25.5% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jeff Yass's ASBP Position: Q2 2025 in Review

Jeff Yass sold out of Aspire Biopharma (ASBP) in Q2 2025, closing a stake of 13 shares — an estimated $9.34K sold.

Jeff Yass first reported a position in ASBP in Q1 2025 and held it in 1 quarter. The position peaked at $9.34K in Q1 2025. 14 funds tracked by Wall St. Rank hold ASBP as of Q2 2025.

Jeff Yass reported no remaining Aspire Biopharma position as of Q2 2025 after selling out during the quarter.
Jeff Yass sold 13 Aspire Biopharma shares in Q2 2025, an estimated $9.34K.
Jeff Yass first reported a position in Aspire Biopharma in Q1 2025 and held it in 1 quarter.
Jeff Yass's Aspire Biopharma position peaked at $9.34K in Q1 2025.
14 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2025.

Based on Susquehanna International Group's 13F filing for Q2 2025, filed 14 Aug 2025.